about
Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-Methyl-D-aspartate antagonist-induced alteration of neuronal firing in prefrontal cortexHomers regulate drug-induced neuroplasticity: implications for addictionThe impact of gender on treatment effectiveness of body psychotherapy for negative symptoms of schizophrenia: A secondary analysis of the NESS trial data.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia.Negative symptoms in schizophrenia: a review.Negative symptoms in schizophrenia.Negative symptoms: psychopathological modelsNegative symptoms in nondeficit syndrome respond to neuroleptic treatment with changes in plasma homovanillic acid concentrations.Should the treatment of schizophrenia include old antipsychotic drugs?High-frequency prefrontal repetitive transcranial magnetic stimulation for the negative symptoms of schizophrenia: a case series.World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.Symptom dimensions and outcome in schizophreniaDevelopments in the pharmacological treatment of schizophrenia.State of the art of drug treatment of schizophrenia and the future position of the novel/atypical antipsychotics.Do negative symptoms of schizophrenia change over time? A meta-analysis of longitudinal data.Are Negative Symptoms Dimensional or Categorical? Detection and Validation of Deficit Schizophrenia With Taxometric and Latent Variable Mixture Models.Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials.Can mental health interventions change social networks? A systematic review.A group cognitive-behavioral and process-oriented approach to treating the social impairment and negative symptoms associated with chronic mental illness.Schizophrenia, co-occurring substance use disorders and quality of care: the differential effect of a managed behavioral health care carve-out.Persistent negative symptoms in schizophrenia: an overview.Substance dependence and remission in schizophrenia: A comparison of schizophrenia and affective disordersOvercoming Disembodiment: The Effect of Movement Therapy on Negative Symptoms in Schizophrenia-A Multicenter Randomized Controlled Trial.Negative symptoms, defect state and Huber's basic symptoms: a comparison of the concepts.Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia.White matter alterations in deficit schizophrenia.Assessment of trait and state aspects of depression in schizophrenia.Experimental models of schizophrenia.Chronic nicotine attenuates phencyclidine-induced impulsivity in a mouse serial reaction time task.Depression in schizophrenia: current guidelines to treatment.A study on negative and depressive symptom prevalence in individuals at ultra-high risk for psychosis.Schizophrenia and the life cycle.Schizophrenic disorder and social functioning.Postimperative negative variation and skin conductance response in chronic DSM-III-R schizophrenia.Review: treatment of schizophrenia. State of the art.[Who are the patients treated in an outpatient clinic with high dosage neuroleptics?]The relationship of negative schizophrenia to parkinsonism.Schizophrenia. A cognitive model and its implications for psychological intervention.Positive and negative syndromes in schizophrenia as a function of chronicity.
P2860
Q24602550-D9735A44-C8EB-4EA9-AA85-8E2C044221F2Q30491852-01D89BFA-3FA5-4720-BE33-A0363221305FQ31143748-FABEAFCA-726B-4F00-AA8B-460BFD17EF8AQ33223628-384810CE-D7B3-420A-9483-02AE2636D651Q33235110-3FBEDE9C-DBB5-4C8A-B9F5-82F839A5B8FBQ33364180-DC593D01-C275-4BCF-812F-D161E8CCD548Q33820512-729E12DF-FE39-452B-B2B2-96949F05D8C0Q33920833-6823F3BB-4B8D-4527-9258-6499A8DA2F38Q33921723-716EF95C-1D2F-423A-B33C-9F01FE7A8469Q34108518-71A020DD-7525-4D5B-94D4-EC792ED177C4Q34590128-5D98D73B-9D7B-4AE2-A940-A2540CB08105Q34640811-7ED934A4-8117-403D-A947-ACB806D698E0Q34884773-2123CE4D-00CC-41CA-9363-9DC6D8E9EC50Q34974846-1CBE50FD-A90F-4535-AFBF-09A7C31D1AADQ35073834-2349365C-9059-4CD7-8E3A-C3DD107CD7D8Q35450483-0E4AB579-B022-455F-A1C6-3F50183FE0E1Q35738993-85FACE9B-688E-42E6-80E9-27D8A5B24B3DQ35738997-BAF1E4B2-B850-442A-A6CF-73D2D4B87523Q35847754-F2B42F62-8851-4935-8A49-05AD47EF5E88Q35900121-31E1D64F-FAEF-40D1-ACAB-FA7C9E419C20Q36157396-8478D1AE-C53E-42A2-8480-E9CC2FC24608Q36651056-E35154F3-42FE-4C7F-8A3A-8D4F92D202EFQ36712877-16742973-CEC3-4BED-89E5-63AD13676A41Q36748682-6E9A6C85-E987-4CBD-BB39-990C98407249Q37039975-A6A676DF-36A7-441D-89E1-F52D644E07C4Q37062577-82643078-80D1-40D9-A879-44BD65794BD3Q37159928-474CB03A-2C3D-4945-A384-2B28BDAFEDF5Q37451474-762EFDA3-678E-43C8-9EB3-883B4C73527EQ37453042-A636AC4F-5770-40D3-B309-5612D032534EQ37574314-52432517-CAB4-4155-9157-DDADBF5056E4Q38783206-713C16F2-4895-496E-B5D2-24D187EC59BAQ38819011-65E0125E-7F78-46B4-86C0-CBE115BFD128Q40452041-3616B242-44A6-4164-A457-38DDBF4B370CQ40849160-BCB74E8F-1C46-4002-8DBE-02ADCF285C0AQ41106382-2AA147DE-4753-4867-BC7F-997C4D7B1DE6Q41156710-26D64881-DE84-4FB3-8B0F-2FBCC1B78C18Q41173472-8C1AFC5A-80B3-4E45-858C-13D80B9E4A88Q41178359-3C51D7D2-06F5-43E9-B448-9EF68C06C21EQ41231694-2E2C94ED-7249-417E-B89D-DF2245AE57E3Q41346456-199FD2B1-8900-4F7A-91AF-D26AA7B3AAEF
P2860
description
1985 nî lūn-bûn
@nan
1985年の論文
@ja
1985年論文
@yue
1985年論文
@zh-hant
1985年論文
@zh-hk
1985年論文
@zh-mo
1985年論文
@zh-tw
1985年论文
@wuu
1985年论文
@zh
1985年论文
@zh-cn
name
Treatment of negative symptoms.
@en
type
label
Treatment of negative symptoms.
@en
prefLabel
Treatment of negative symptoms.
@en
P2093
P356
P1476
Treatment of negative symptoms.
@en
P2093
Carpenter WT Jr
Heinrichs DW
P304
P356
10.1093/SCHBUL/11.3.440
P407
P577
1985-01-01T00:00:00Z